In conjunction with Oragenics, announced selection of lead clinical candidate for the lantibiotics
program and reported positive in vivo efficacy data in critical animal study on multiple compounds from Oragenics' Mutacin 1140 platform.
In addition to food safety benefits, lantibiotics
are easy to digest, nontoxic, do not induce allergies and are difficult for dangerous bacteria to develop resistance against.
The bacteriocins of lactic acid-fermenting bacteria are called lantibiotics
have potent anti-infective properties but have historically been underexploited owing to a lack of research tools, a challenge that Novacta has successfully addressed through its proprietary technology platform.
Mutacin 1140 and nisin A, are posttranslationally modified peptide antibiotics belonging to a family of antibiotics called type A lantibiotics
Their effort includes the analysis and exploitation of natural antimicrobial phenomena such as lantibiotics
, bacteriocins and bacteriophage lysins.
This demonstrates significant progress toward the commercial production of its lead lantibiotic
, MU1140, and delivers an important step in validating the lantibiotics
platform targeting infectious diseases.
The collaboration recently demonstrated initial success in producing improved titers of Oragenic's lead compound MU1140 through a genetically engineered host, progressing toward the goal of commercial production of lantibiotics
Oragenics is making progress with both our exclusive channel collaboration with Intrexon on novel lantibiotics
and with our ProBiora3 containing oral probiotics for humans and pets.
The researchers found that certain lantibiotics
, and MU1140(TM) in particular, exert their killing action on bacteria by binding to and hijacking Lipid II, a molecule which is required for bacterial cell growth.
Oragenics is moving forward on a number of fronts, including our collaboration with Intrexon on novel lantibiotics
and our Evora line of oral probiotics for humans and pets," states Dr.
AntexPharma has recently licensed new antibiotic compounds from the University of Maryland; these new lantibiotics
have been shown to kill a broad spectrum of disease-causing bacteria, including the major resistant nosocomial pathogens, methicillin-resistant Staphylococcus aureus ("RSA", vancomycin-resistant enterococci ("VRE"), Streptococcus, Pseudomonas, Escherichia coli, and Klebsiella.